AR and metastatic prostate carcinoma: LNCaP and LAPC4 are AR responsive, while DU-145 is resistant to AR therapy71, allowing us to evaluate the system’s response to AR-targeted and chemotherapy treatments commonly used to treat patients with metastatic prostate cancer in the bone.